Form 4: CEO Blum Boosts CYTK Stake with Performance Shares
Insider Transaction Report
Cytokinetics CEO Robert I. Blum increased his beneficial ownership through performance share awards, partially offset by tax-related share withholding.
Summary
- Robert I. Blum, President & CEO and Director of Cytokinetics Inc. (CYTK), reported transactions on December 22, 2025.
- He acquired 5,765 shares of common stock as performance shares, which remain subject to a one-year time vesting requirement.
- He also acquired an additional 5,765 shares of common stock from vested Performance Stock Units.
- A disposition of 2,935 shares of common stock occurred at a price of $62.72 per share for tax withholding purposes related to the earned and vested performance shares.
- Following these transactions, Mr. Blum directly owns 399,604 shares of common stock.
- Additionally, 4,166 shares are indirectly owned through two irrevocable trusts (2,083 shares each).
Sentiment
Score: 7
Explanation: The CEO's acquisition of performance-based shares indicates confidence in the company's performance and future, despite a portion being sold for tax purposes.
Positives
- CEO Robert I. Blum earned a total of 11,530 shares of common stock through performance-based awards, indicating the achievement of company performance goals.
- A portion of these shares (5,765) from Performance Stock Units are already vested, demonstrating immediate reward for performance.
Negatives
- 2,935 shares were disposed of at $62.72 per share to cover tax obligations, which reduced the net increase in direct beneficial ownership.
Risks
- NA
Future Outlook
NA
Industry Context
NA
Comparison to Industry Standards
- NA
Related Party Transactions
- Shares are indirectly held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust, which are related parties to Robert I. Blum.
Stakeholder Impact
- Shareholders may view the CEO's increased stake as a positive signal of management's alignment with shareholder interests and confidence in the company's future.
Next Steps
- The 5,765 performance shares acquired on December 22, 2025, remain subject to a 1-year time vesting requirement.
Key Dates
| Date | Description |
|---|---|
| 12/22/2025 | Date of earliest transaction for acquisition and disposition of common stock. |
| 12/24/2025 | Signature date of the reporting person's attorney-in-fact. |
Keywords
Cytokinetics, CYTK, Robert I. Blum, Insider Trading, Form 4, Performance Shares, Stock Awards, CEO, Director, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.